Related Experiment Videos
Chronic obstructive pulmonary disease: emerging therapies
1Department of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA. douglas_w_hay@sbphrd.com
Abstract:
Despite the high prevalence of and mortality from chronic obstructive pulmonary disease, extensive research on the underlying pathophysiology and specific therapeutics for this disease is, relatively, in its infancy. Several novel molecular targets are being investigated as potential treatments for the disease. The most exciting new class of compounds is the phosphodiesterase 4 inhibitors; Ariflo (SB 207499)-a member of this class, and the most advanced in development (Phase III)-was reported recently to have significant clinical efficacy in patients with chronic obstructive pulmonary disease. Phosphodiesterase 4 inhibitors, such as Ariflo, possibly represent the most important advance in pulmonary medicine in recent years.
Insights
New phosphodiesterase 4 inhibitors, like Ariflo, show significant clinical efficacy for chronic obstructive pulmonary disease (COPD). This promising therapeutic class represents a major advance in pulmonary medicine for treating COPD patients.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) has high prevalence and mortality rates.
- Research into COPD pathophysiology and therapeutics is still developing.
- Novel molecular targets are under investigation for COPD treatment.
Purpose of the Study:
- To investigate the efficacy of novel therapeutics for chronic obstructive pulmonary disease.
- To highlight the potential of phosphodiesterase 4 inhibitors as a new treatment class.
Main Methods:
- Clinical trials evaluating novel compounds.
- Focus on Ariflo (SB 207499), a phosphodiesterase 4 inhibitor in Phase III development.
Main Results:
- Ariflo demonstrated significant clinical efficacy in COPD patients.
- Phosphodiesterase 4 inhibitors are a promising new class of compounds.
Conclusions:
- Phosphodiesterase 4 inhibitors, exemplified by Ariflo, represent a significant advancement in pulmonary medicine.
- These inhibitors offer potential for improved COPD management.